Skip to main content
. Author manuscript; available in PMC: 2021 Jul 18.
Published in final edited form as: Nat Med. 2020 May 11;26(5):693–698. doi: 10.1038/s41591-020-0860-1

Figure 2. On-treatment changes in plasma IL8 and overall survival (OS) in mUC patients treated with atezolizumab or chemotherapy.

Figure 2.

a, On-treatment changes in plasma IL8 (pIL8) are expressed as the ratio of pIL8 level on treatment cycle 3 day 1 (C3D1) and baseline (cycle 1 day 1, C1D1). High on-treatment increases in pIL8 (median cutoff: 1.09 pg/mL) were significantly associated with worse OS in cohort 2 of IMvigor210 (HR: 2.09, 95% CI: 1.32, 3.30, P=1.55e-3). b, High on-treatment increase in pIL8 was significantly associated with worse OS in the atezolizumab arm (HR: 2.01, 95% CI: 1.49, 2.71, P=6.09e-6), but not in the chemotherapy arm of IMvigor211 (HR: 1.17, 95% CI: 0.89; 1.55, P=0.27). The HRs were calculated using stratified Cox proportional hazard regression models, and P values were calculated using stratified log-rank test. P values were adjusted for multiple comparisons. Multivariate analyses adjusted HRs for age, sex, race, ECOG performance status, presence of liver metastasis, and tumor burden (SLD).

HHS Vulnerability Disclosure